We performed an immunohistochemical study on 5 normal marrow samples and 3 fibrotic marrow samples to investigate the cellular distribution of various isoforms of platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), basic fibroblast growth factor (bFGF), and their corresponding receptors. Immature hematopoietic precursors strongly expressed PDGF-B, all the TGF-β isoforms, PDGFRβ, TGFβRI and II, and FGFR1, 3, and 4. Megakaryocytes stained primarily for PDGF-B, TGF-β2–3, and PDGFRβ. Histiocytes displayed intense TGF-β1, bFGF, and FGFR2 expression. Fibroblasts and endothelial cells carried receptors for all the aforementioned cytokines. The last 2 cell types also expressed the ligand cytokines to varied degrees.

Keywords:
Basic fibroblast growth factor, Bone marrow, Cytokine, Immunohistochemistry, Isotype, Myelofibrosis, Platelet-derived growth factor, Receptors, Transforming growth factor-β
1.
Reilly JT: Idiopathic myelofibrosis: Pathogenesis, natural history and management. Blood Rev 1997;11:233–242.
2.
Siegbahn A, Hammacher A, Westermark B, Heldin CH: Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990;85:916–920.
3.
Kimura A, Katoh O, Kuramoto A: Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br J Haematol 1988;69:9–12.
4.
Bonner JC, Osornio-Vargas AR, Badgett A, Brody AR: Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor-AA, -AB, and -BB isoforms secreted by rat alveolar macrophages. Am J Respir Cell Mol Biol 1991;5:539–547.
5.
Osornio-Vargas AR, Goodell AL, Hernandez-Roderiguez NA, Brody AR, Coin PG, Badgett A, Bonner JC: Platelet-derived growth factor (PDGF)-AA, -AB, and -BB induce differential chemotaxis of early-passage rat lung fibroblasts in vitro. Am J Respir Cell Mol Biol 1995;12:33–40.
6.
Heldin CH, Westermark B: Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul 1990;1:555–566.
7.
Fava RA, Casey TT, Wilcox J, Pelton RW, Moses HL, Nanney LB: Synthesis of transforming growth factor-beta 1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-granules. Blood 1990;76:1946–1955.
8.
Kimura A, Katoh O, Hyodo H, Kuramoto A: Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989;72:486–491.
9.
Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597–641.
10.
Shah M, Foreman DM, Ferguson MW: Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985–1002.
11.
Lopez-Casillas F, Wrana JL, Massague J: Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993;73:1435–1444.
12.
Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341–347.
13.
Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775–785.
14.
Ratajczak MZ: Fibroblast growth factors and early hemopoietic cell development. Leuk Lymphoma 1997;27:221–229.
15.
Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993;81:631–638.
16.
Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95–114.
17.
Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292–15297.
18.
Bikfalvi A, Han ZC: Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994;8:523–529.
19.
Battegay EJ: Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333–346.
20.
Hino M, Tojo A, Miyazono K, Urabe A, Takaku F: Effects of type beta transforming growth factors on hematopoietic progenitor cells. Br J Haematol 1988;70:143–147.
21.
Allouche M: Basic fibroblast growth factor and hematopoiesis. Leukemia 1995;9:937–942.
22.
Yanagida M, Ide Y, Imai A, Toriyama M, Aoki T, Harada K, Izumi H, Uzumaki H, Kusaka M, Tokiwa T: The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997;99:739–745.
23.
Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, McNiece IK: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 1996;88:402–409.
24.
Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA: Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981;57:781–787.
25.
Schmitz B, Thiele J, Kaufmann R, Witte O, Wickenhauser C, Kuhn-Regnier F, Fischer R: Megakaryocytes and fibroblasts – interactions as determined in normal human bone marrow specimens. Leuk Res 1995;19:629–637.
26.
Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F: Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991;77:80–86.
27.
Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, Dupriez B: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441–448.
28.
Dalley A, Smith JM, Reilly JT, Neil SM: Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996;93:856–862.
29.
Rameshwar P, Chang VT, Thacker UF, Gascon P: Systemic transforming growth factor-beta in patients with bone marrow fibrosis – pathophysiological implications. Am J Hematol 1998;59:133–142.
30.
Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Jaffe F, Praloran V, Dupriez B, Demory JL, Jasmin C, Martyre MC: Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88:4534–4546.
31.
Zauli G, Visani G, Catani L, Vianelli N, Gugliotta L, Capitani S: Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount in patients with essential thrombocythaemia. Br J Haematol 1993;83:14–20.
32.
Rougier F, Dupuis F, Denizot Y: Human bone marrow fibroblast – an overview of their characterization, proliferation and inflammatory mediator production. Hematol Cell Ther 1996;38:241–246.
33.
Keutzer JC, Sytkowski AJ: Regulated production of a pleiotropic cytokine-platelet-derived growth factor – by differentiating erythroid cells in vitro and in vivo. Proc Natl Acad Sci USA 1995;92:4967–4971.
34.
Yang M, Chesterman CN, Chong BH: Recombinant PDGF enhances megakaryocytopoiesis in vitro. Br J Haematol 1995;91:285–289.
35.
Bonnet D, Lemoine FM, Najman A, Guigon M: Comparison of the inhibitory effect of AcSDKP, TNF-alpha, TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors. Exp Hematol 1995;23:551–556.
36.
Sytkowski AJ, O’Hara C, Vanasse G, Armstrong MJ, Kreczko S, Dainiak N: Characterization of biologically active, platelet-derived growth factor-like molecules produced by murine erythroid cells in vitro and in vivo. J Clin Invest 1990;85:40–46.
37.
Dainiak N, Davies G, Kalmanti M, Lawler J, Kulkarni V: Platelet-derived growth factor promotes proliferation of erythropoietic progenitor cells in vitro. J Clin Invest 1983;71:1206–1214.
38.
Delwiche F, Raines E, Powell J, Ross R, Adamson J: Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells. J Clin Invest 1985;76:137–142.
39.
Tefferi A: Pathogenetic mechanisms in chronic myeloproliferative disorders: Polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Semin Hematol 1999;36(suppl 2): 3–8.
40.
Johnston JB, Dalal BI, Israels SJ, Oh S, McMillan E, Begleiter A, Michaud G, Israels LG, Greenberg AH: Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells. Am J Clin Pathol 1995;103:574–582.
41.
Hammacher A, Hellman U, Johnsson A, Ostman A, Gunnarsson K, Westermark B, Wasteson A, Heldin CH: A major part of platelet-derived growth factor purified from human platelets is a heterodimer of one A and one B chain. J Biol Chem 1988;263:16493–16498.
42.
Katoh O, Kimura A, Itoh T, Kuramoto A: Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 1990;35:145–150.
43.
Gladwin AM, Carrier MJ, Beesley JE, Lelchuk R, Hancock V, Martin JF: Identification of mRNA for PDGF B-chain in human megakaryocytes isolated using a novel immunomagnetic separation method. Br J Haematol 1990;76:333–339.
44.
Sariban E, Kufe D: Expression of the platelet-derived growth factor 1 and 2 genes in human myeloid cell lines and monocytes. Cancer Res 1988;48:4498–4502.
45.
Malden LT, Chait A, Raines EW, Ross R: The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J Biol Chem 1991;266:13901–13907.
46.
Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasaharan M, Malden LT, Masuko H, Sato H: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990;248:1009–1012.
47.
Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y: Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br J Haematol 1994;86:303–307.
48.
Collins T, Ginsburg D, Boss JM, Orkin SH, Pober JS: Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis. Nature 1985;316:748–750.
49.
Coker RK, Laurent GJ, Shahzeidi S, Lympany PA, du Bois RM, Jeffery PK, McAnulty RJ: Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol 1997;150:981–991.
50.
Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R: Human transforming growth factor-beta 3: Recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol 1989;3:1977–1986.
51.
Ellis IR, Schor SL: Differential motogenic and biosynthetic response of fetal and adult skin fibroblasts to TGF-beta isoforms. Cytokine 1998;10:281–289.
52.
Thiele J, Braeckel C, Wagner S, Falini B, Dienemann D, Stein H, Fischer R: Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: An immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. Virchows Arch A Pathol Anat Histopathol 1992;421:33–39.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.